| The board of Hester Biosciences at its meeting held on 11 March 2026 has approved the divestment of 43.81% equity stake out of total 54.81% in its subsidiary, Texas Lifesciences (TLPL), by way of transfer/sale of shares to the existing promoter shareholders of the TLPL for a consideration of Rs 9.2 crore. <p> TLPL is not material subsidiary of the Company. TLPL will ceased to be the subsidiary of the Company upon completion share transfer transaction as above. <p> Hester will continue to do business with TLPL and maintain an 11% equity stake/investment in the company. |